Drug nanocrystals-the universal formulation approach for poorly soluble drugs

Nanoparticulate Drug Delivery Systems

Volumn , Issue , 2007, Pages 71-88

  Möschwitzer, Jan ^a   Müller, Rainer H ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85055809757     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (78)

1. Merisko-Liversidge E. Nanocrystals: resolving pharmaceutical formulation issues associated with poorly water-soluble compounds in particles. Orlando: Marcel Dekker, 2002.
2. Lipinski C. Poor aqueous solubility-an industry wide problem in drug delivery. Am Pharm Rev 2002; 5:82-85.
3. FDA. Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. FDA, 2000.
4. Kanfer I. Report on the international workshop on the biopharmaceutics classification system (BCS): scientific and regulatory aspects in practice. J Pharm Pharm Sci 2002; 5(1):1-4.
5. Gupta PK, Patel JP, Hahn KR. Evaluation of pain and irritation following local administration of parenteral formulations using the rat paw lick model. J Pharm Sci Technol 1994; 48(3):159-166.
6. Singla AK, Garg A, Aggarwal D. Paclitaxel and its formulations. Int J Pharm 2002; 235(1-2):179-192.
7. Mattila MA, Suistomaa M. Intravenous premedication with diazepam: a comparison between two vehicles. Anaesthesia 1984; 39(9):879-882.
8. Uekama K. Design and evaluation of cyclodextrin-based drug formulation. Chem Pharm Bull (Tokyo) 2004; 52(8):900-915.
9. Müller RH, Peters K, Becker R, Kruss B. Nanosuspensions: a novel formulation for the i.v. administration of poorly soluble drugs. First World Meeting APGI/APV, Budapest, 1995.
10. List M, Sucker H. Hydrosols of pharmacologically active agents and their pharmaceutical compositions comprising them. US 5,389,382, 1991.
11. Kipp JE. The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs. Int J Pharm 2004; 284(1-2):109-122.
12. Müller RH, Böhm BHL. Nanosuspensions. In: Müller RH, Benita S, Böhm B, eds. Emulsions and Nanosuspensions for the Formulation of Poorly Soluble Drugs. Stuttgart: Medpharm, 1998:149-174.
13. Troester F. Cremophor-free aqueous paclitaxel nanosuspension-production and chemical stability. Controlled Release Society 31st annual meeting, Honolulu, HI, 2004.
14. Liversidge E, Wei L. Stabilization of chemical compounds using nanoparticulate formulations. US 2001;952032 20010914. CAN 138:243327, US 2003054042 A1, 2003.
15. Möschwitzer J, Achleitner G, Pomper H, Muller RH. Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension technology. Eur J Pharm Biopharm 2004; 58(3):615-619.
16. Müller RH, Keck CM. Challenges and solutions for the delivery of biotech drugs-a review of drug nanocrystal technology and lipid nanoparticles. J Biotechnol 2004; 113(1-3):151-170.
17. Liversidge GG, Cundy KC. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs. I Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int J Pharm 1995; 125:91-97.
18. Merisko-Liversidge E, Liversidge GG, Cooper ER. Nanosizing: a formulation approach for poorly water-soluble compounds. Eur J Pharm Sci 2003; 18(2):113-120.
19. Liversidge GG, Conzentino, Phil. Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. Int J Pharm 1995; 125:309-313.
20. Eickhoff WM, Engers DA, Mueller KR. Nanoparticulate NSAID compositions, Application. US 95-385614, 5518738, 1996.
21. Jacobs C, Kayser O, Müller RH. Production and characterisation of mucoadhesive nanosuspensions for the formulation of bupravaquone. Int J Pharm 2001; 214(1-2):3-7.
22. Müller RH, Jacobs C. Buparvaquone mucoadhesive nanosuspension: preparation, optimisation and long-term stability. Int J Pharm 2002; 237(1-2):151-161.
23. Lamprecht A, Ubrich N, Yamamoto H, et al. Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. J Pharmacol Exp Ther 2001; 299(2):775-781.
24. Hussain N, Jaitley V, Florence AT. Recent advances in the understanding of uptake of microp-articulates across the gastrointestinal lymphatics. Adv Drug Deliv Rev 2001; 50(1-2):107-142.
25. Na GC, Stevens Jr J, Yuan BO, Rajagopalan N. Physical stability of ethyl diatrizoate nanocrystalline suspension in steam sterilization. Pharm Res 1999; 16(4):569-574.
26. Müller RH, Jacobs C, Kayser O. Nanosuspensions for the formulation of poorly soluble drugs. In: Nielloud F, Marti-Mestres G, eds. Pharmaceutical Emulsions and Suspensions. New York: Marcel Dekker, 2000:383-407.
27. Böhm B. Production and characterisation of nanosuspensions as novel delivery system for drugs with low bioavailability. In: Pharmaceutical Technology. Berlin: Free University of Berlin, 1999.
28. Peters K et al. Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. J Antimicrob Chemother 2000; 45(1):77-83.
29. Scholer N et al. Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis. Antimicrob Agents Chemother 2001; 45(6):1771-1779.
30. Ostrander KD, Bosch HW, Bondanza DM. An in vitro assessment of a NanoCrystal beclomethasone dipropionate colloidal dispersion via ultrasonic nebulization. Eur J Pharm Biopharm 1999; 48(3): 207-215.
31. Jacobs C, Müller RH. Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharm Res 2002; 19(2):189-194.
32. Wiedmann TS, DeCastro L, Wood RW. Nebulization of NanoCrystals: production of a respirable solid-in-liquid-in-air colloidal dispersion. Pharm Res 1997; 14(1):112-116.
33. Kraft WK et al. The pharmacokinetics of nebulized nanocrystal budesonide suspension in healthy volunteers. J Clin Pharmacol 2004; 44(1):67-72.
34. Mainardes RM et al. Colloidal carriers for ophthalmic drug delivery. Curr Drug Targets 2005; 6(3):363-371.
35. Keipert S. Ophtalmika: etablierte Arzneiformen und neue Konzepte. In: Müller RH, Hildebrand GE, eds. Pharmazeutische Technologie: Moderne Arzneiformen. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH, 1998:77-98.
36. Pahl MH. Zerkleinerungstechnik. Praxiswissen Verfahrenstechnik. Köln: TÜV Rheinland GmbH, 1991.
37. Liversidge GG, Cundy KC, Bishop JF, Czekai DA. Surface Modified Drug Nanoparticles. USA, 1992.
38. Buchmann S, Fischli W, Thiel FP, Alex R. Aqueous microsuspension, an alternative intravenous formulation for animal studies. In: 42nd annual congress of the International Association for Pharmaceutical Technology (APV), Mainz, 1996.
39. Bruno JAD, Brian D. Gustow Evan, Illig, Kathleen J, Rajagopalan, Nats, Sarpotdar. Method of grinding pharmaceutical substances. US 5,518,187, 1992.
40. Möschwitzer J. Pharmaceutical Technology. Ph.D. Thesis. Berlin, Free University of Berlin. In preparation.
41. Cunningham JL, Elaine, Cooper, Eugene R, Liversidge, Gary G. Milling microgram quantities of nanoparticulate candidate compounds. US 20040173696, 2004.
42. Wyeth Research Drug Information, Rapamune (Sirolumus) Oral Solutions and Tablets. Company Communications, 2004.
43. Merck, Drug Information Emend. 2004.
44. Violanto MR. Method for making uniformly sized particles from water-insoluble organic compounds. US 4,826,689, 1989.
45. Sucker H. Hydrosole, eine Alternative für die parenterale Anwendung von schwer wasserlöslichen Wirkstoffen. In: Müller RH, Hildebrand GE, eds. Pharmazeutische Technologie: Moderne Arzneiformen. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH, 1998:383-391.
46. Auweter H, Bohn H. Luddecke E. Stable, aqueous dispersions and stable, water-dispersible dry powders of xanthophylls, their production and their use, Application. WO 2000-EP3467, 2000066665, 2000.
47. Mueller BW, Rasenack, Norbert. Method for the production and the use of microparticles and nano-particles by constructive micronisation. WO 002003080034A3, 2003.
48. Rasenack N, Hartenhauer H, Müller BW. Microcrystals for dissolution rate enhancement of poorly water-soluble drugs. Int J Pharm 2003; 254(2):137-145.
49. Parikh IS, Ulagaraj. Composition and method of preparing microparticles of water-insoluble substances. 93969997, 1997.
50. Dearn AR. Atovaquone pharmaceutical compositions. US, 974248, 6,018,080, 2000.
51. Haynes DH. Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs. US 5,091,187, 1992.
52. Müller RHB, Robert, Kruss, Bernd, Peters, Katrin. Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit.
53. Müller RHJCK O. DissoCubes-a novel formulation for poorly soluble and poorly bioavailable drugs, In: Roberts MJRJHMS, ed. Modified-Release Drug Delivery Technology. New York: Marcel Dekker, 2003:135-149.
54. Müller RH, Möschwitzer J, Bushrab FN. Manufacturing of nanoparticles by milling and homogenisation techniques. In: Kompella G, ed. Nanoparticle Technology for Drug Delivery. New York: Marcel Dekker. Submitted.
55. Müller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the future. Adv Drug Deliv Rev 2001; 47(1):3-19.
56. Grau MJ, Kayser O, Müller RH. Nanosuspensions of poorly soluble drugs-reproducibility of small scale production. Int J Pharm 2000; 196(2):155-159.
57. Müller RH, Peters K. Nanosuspensions for the formulation of poorly soluble drugs. I. Preparation by a size-reduction technique. Int J Pharm 1998; 160(2):229-237.
58. Müller RH, Böhm BHL, Grau MJ. Nanosuspensions-a formulation approach for poorly soluble and poorly bioavailable drugs. In: Wise DL, ed. Handbook of Pharmaceutical Controlled Release. New York: Marcel Dekker, 2000:345-357.
59. Müller RH, Krause K, Mader K. Method for controlled production of ultrafine microparticles and nanoparticles, Application. WO 2000-EP6535, 2001003670, 2001.
60. Bushrab FN, Müller RH. Drug nanocrystals: Amphotericin B-containing capsules for oral delivery. Philadelphia: AAPS, 2004.
61. Liedtke S et al. Influence of high pressure homogenisation equipment on nanodispersions characteristics. Int J Pharm 2000; 196(2):183-185.
62. Krause KP et al. Heavy metal contamination of nanosuspensions produced by high-pressure homogenisation. Int J Pharm 2000; 196(2):169-172.
63. Krause KP, Müller RH. Production and characterisation of highly concentrated nanosus-pensions by high pressure homogenisation. Int J Pharm 2001; 214(1-2):21-24.
64. Kipp JEW, Joseph Chung Tak, Doty, Mark J, Rebbeck, Christine L. Microprecipitation method for preparing submicron suspensions. US 6,869,617, 2001.
65. Möschwitzer. Method for the production of ultra-fine submicron suspensions. DE 10 2005 011 786.4, 2005.
66. Müller RH, Möschwitzer J. Oral drug nanocrystal formulations based on non-aqueous/ water-reduced homogenization technology. In: Annual meeting of the Controlled Release Society, Miami, 2005.
67. Möschwitzer JP, Lemke A. Method for the gentle production of ultrafine particle suspensions, Germany. DE 10 2005 017 777.8, 2005.
68. Hu J, Johnston KP, Williams RO III. Spray freezing into liquid (SFL) particle engineering technology to enhance dissolution of poorly water soluble drugs: organic solvent versus organic/aqueous co-solvent systems. Eur J Pharm Sci 2003; 20(3):295-303.
69. Chen X et al. Preparation of cyclosporine as nanoparticles by evaporative precipitation into aqueous solution. Int J Pharm 2002; 242(1-2):3-14.
70. Grau M. Investigation of dissolution velocity, saturation solubility and stability of ultrafine drug suspensions. Dissertation. Pharmazeutische Technologie. Berlin: Free University of Berlin, 2000.
71. Stewart PJ, Zhao FY. Understanding agglomeration of indomethacin during the dissolution of micronised indomethacin mixtures through dissolution and de-agglomeration modeling approaches. Eur J Pharm Biopharm 2005; 59(2):315-323.
72. Kirkof N. Creation and characterization of Nanoparticles. In: 32nd annual meeting and exposition of the Controlled Release Society, Miami, 2005.
73. Möschwitzer J, Müller RH. From the drug nanocrystal to the final mucoadhesive oral dosage form, 2004.
74. Möschwitzer J, Müller RH. Spray coated pellets as carrier system for mucoadhesive drug nanocrystals. Eur J Pharm Biopharm. Submitted.
75. Möschwitzer J, Müller RH. Controlled drug delivery system for oral application of drug nanocrystals. In: 2004 AAPS annual meeting and exposition, Baltimore, MD, 2004.
76. Bushrab NF, Müller RH. Nanocrystals of poorly soluble drugs for oral administration. NewDrugs 2003; 5:20-22.
77. Bushrab FN, Müller RH. Drug nanocrystals for oral delivery-compounds by spray drying. Philadelphia: AAPS, 2004.
78. Müller RH. Preparation of a matrix material-excipient compound containing a drug. WO 1997-EP6893, WO 9825590, 1998.